GRI
GRI Bio, Inc.
$1.45
+2.11%
2026-10-23
About GRI Bio, Inc.
GRI Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies that target diseases leading to inflammatory, fibrotic, and autoimmune disorders in the United States. Its lead product candidate is GRI-0621, an oral inhibitor of type 1 Natural Killer T cells, which is in phase IIa clinical trial for the treatment of severe fibrotic lung diseases, such as idiopathic pulmonary fibrosis. The company's portfolio also includes GRI-0803, a novel oral agonist of type 2 Natural Killer T cells that is in preclinical development for the treatment of autoimmune disorders; a proprietary library of 500+ compounds; and GRI-0124 and GRI-0729 for balance inflammatory immune responses. The company was formerly known as Glycoregimmune, Inc. GRI Bio, Inc. was founded in 2009 and is based in LA Jolla, California.
Key Fundamentals
P/E Ratio
0.04
Forward P/E
-1.02
EPS (TTM)
$-2.83
ROE
-142.0%
Profit Margin
0.0%
Debt/Equity
0.43
Price/Book
0.44
Beta
-0.55
Market Cap
$4.5M
Avg Volume (10D)
118K
Recent Breakout Signals
Recent Price Range (60 Days)
60D High
$3.36
60D Low
$1.36
Avg Volume
353K
Latest Close
$1.45
Get breakout alerts for GRI
Sign up for Breakout Scanner to receive daily notifications when GRI triggers breakout signals. Build custom AI screeners and backtest strategies.
Create your account7-day free trial, no card needed. Then $20/month.
GRI Bio, Inc. (GRI) is listed on the NASDAQ (NASDAQ). Breakout Scanner monitors GRI daily for breakout patterns including long-term ceiling breakouts, momentum breakouts, and near-breakout watch setups. GRI operates in the Healthcare sector within the Biotechnology industry. Data is provided for informational purposes only and does not constitute financial advice.